Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron for Stress Urinary Incontinence in Women With Overweight or Obesity
jRCT2031250467Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2025
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of orforglipron in stress urinary incontinence (SUI), obesity and Overweight (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from Baseline in Incontinence Episode Frequency (IEF). Started Oct 2025; status: recruiting.
02
Drugs
orforglipron
03
Conditions
stress urinary incontinence (SUI)obesityOverweight
Beyond the preview
Go deeper on jRCT2031250467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250467.